Dr. John Lowe

Internal Medicine
Utah Digestive Health Institute
6028 S Ridgeline Dr Ste 201, 
Ogden, UT 
Utah Digestive Health Institute
6028 S Ridgeline Dr Ste 201, 
Ogden, UT 

Overview

John Lowe is an Internal Medicine provider practicing medicine in Ogden, Utah.

His clinical expertise encompasses Benign Esophageal Stricture, Lower Esophageal Ring, Eosinophilic Esophagitis, and Esophagitis.

He is actively involved in clinical research, co-authoring 1 peer reviewed article and participating in 15 clinical trials.

Specialties

Internal Medicine

Licenses

Internal Medicine in UT

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SelectHealth
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

Utah Digestive Health Institute
6028 S Ridgeline Dr Ste 201, Ogden, UT 84405

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode
Enrollment Status: Active_not_recruiting
Publish Date: May 14, 2026
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Open-label Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE)
Enrollment Status: Terminated
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drug: Budesonide oral suspension
Study Phase: Phase 3
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
A Phase 3, Multicenter, Double-blind Extension Study to Evaluate Maintenance of Efficacy of Oral Budesonide Suspension (OBS) and Long-term Treatment Effect of OBS in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis (EoE)
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Oral Budesonide Suspension (OBS) in Adolescent and Adult Subjects (11 to 55 Years of Age, Inclusive) With Eosinophilic Esophagitis: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 2 (TRuE AD2) - A Phase 3, Double-Blind, Randomized, 8-Week, Vehicle-Controlled Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Adolescents and Adults With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Drug
Study Phase: Phase 3
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Blood Collection Sub-Study of Exact Sciences Protocol 2019-01: Clinical Validation of an Optimized Multi-Target Stool DNA (Mt-sDNA 2.0) Test, For Colorectal Cancer Screening BLUE-C
Enrollment Status: Completed
Publish Date: September 28, 2023
Intervention Type: Other
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
A Randomized, Double-Blind, Parallel-Group, Placebo- and Active-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

1 Total Publications

Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Journal: Gastroenterology
Published: July 22, 2022
Similar Doctors
Expertise in
8
conditions
Dr. Scott Stevens
Internal Medicine
Expertise in
8
conditions
Dr. Scott Stevens
Internal Medicine

Imed Physicians

5121 S Cottonwood St, 
Murray, UT 
 (34.2 miles away)
801-507-3380
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Scott Stevens is a primary care provider, practicing in Internal Medicine in Murray, Utah. Dr. Stevens is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Deep Vein Thrombosis, Mesenteric Venous Thrombosis, Venous Thromboembolism (VTE), Thrombectomy, and Liver Transplant. Dr. Stevens is board certified in American Board Of Internal Medicine. Dr. Stevens is currently accepting new patients.

Expertise in
5
conditions
Dr. Scott Woller
Internal Medicine
Expertise in
5
conditions
Dr. Scott Woller
Internal Medicine

Imed Physicians

5121 S Cottonwood St, 
Murray, UT 
 (34.2 miles away)
801-507-3380
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Scott Woller is a primary care provider, practicing in Internal Medicine in Murray, Utah. Dr. Woller is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Venous Thromboembolism (VTE), Mesenteric Venous Thrombosis, Deep Vein Thrombosis, Thrombectomy, and Knee Replacement. Dr. Woller is board certified in American Board Of Internal Medicine. Dr. Woller is currently accepting new patients.

Expertise in
28
conditions
Dr. Jeffrey H. Call
Internal Medicine
Expertise in
28
conditions
Dr. Jeffrey H. Call
Internal Medicine

McKay-Dee Internal Medicine Clinic

4403 Harrison Boulevard, Suite 3875, 
Ogden, UT 
 (2.0 miles away)
801-387-7950
Experience:
43+ years
Languages Spoken:
English, Korean
See accepted insurances
Offers Telehealth

Jeffrey Call is a primary care provider, practicing in Internal Medicine in Ogden, Utah. He has been practicing medicine for over 43 years. Dr. Call is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Osmotic Diuresis, Atherosclerosis, Coronary Heart Disease, and Anemia.

Frequently Asked Questions about Dr. John Lowe

How do I make an appointment with Dr. John Lowe?

You can book an appointment with Dr. John Lowe by calling their office at 801-475-5400. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John Lowe a top-rated expert for Benign Esophageal Stricture?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John Lowe is classified as an Experienced expert for Benign Esophageal Stricture, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John Lowe specialize in?

While Dr. John Lowe is a Internal Medicine, they have specific expertise in Benign Esophageal Stricture, Lower Esophageal Ring, and Eosinophilic Esophagitis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. John Lowe participate in research or clinical trials?

Yes. Dr. John Lowe has published 1 articles and abstracts on conditions like Benign Esophageal Stricture. You can view a list of Dr. John Lowe's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John Lowe accept my insurance?

Dr. John Lowe accepts most major insurance plans, including Medicaid and SelectHealth. We recommend calling the office directly at 801-475-5400 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lowe's expertise for a condition
ConditionClose
        View All 12 Experienced Conditions
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile